Glycosylation of immunoglobulin light chains is highly prevalent in cold agglutinin disease
Year: 2020
Type: article
Abstract: cells.9,10 In animal models, antagonism of VEGF receptor signaling by genetic or pharmacologic manipulation is associated with TMA, including impaired endothelial cell proliferation and capillary formation with subsequent loss of glomerular and mesangial cells.9,10 To our knowledge, this is the largest published case series describing TMA with bortezomib and ixazomib.These cases are characterized by serious clinical outcomes including death in some instances.Although our analysis is limited by the quality of spontaneous adverse event reporting and other limitations inherent to spontaneous reporting systems (eg, under-reporting, reporting biases), the strong temporal association and biologic plausibility provide evidence supportive of a drug-event causal association between the drugs, bortezomib and ixazomib, and the event, TMA.Additionally, the known association of TMA with carfilzomib suggests this may be a class effect related to proteasome inhibition.3 The US prescribing information for bortezomib and ixazomib was recently updated to include the risk of TMA under warnings and precautions, with recommendations to discontinue PI therapy for suspected TMA.1,2 This revision of the prescribing information is intended to increase clinicians' awareness of the risk for TMA with bortezomib and ixazomib, and to mitigate the risk for serious outcomes by improving the likelihood of early therapeutic interventions.
Source: American Journal of Hematology
DOI: 10.1002/ajh.25843
Institutions: Mayo Clinic, Stanford Medicine, Stanford University
Language: English
Topic: Blood groups and transfusion
Subfield: Hematology
Field: Medicine
Domain: Health Sciences
Open Access status: bronze
OpenAlex ID: W3023802852